23 August 2018 - Rare disease group Swedish Orphan Biovitrum (Sobi) says it has gained NHS England reimbursement for Ravicti for long-term management of urea-cycle disorders in adults and children.

This drug is the first liquid formulation of phenylbutyrate to be offered to patients whose condition cannot be controlled by diet via commissioning centres across England.

A urea cycle disorder is a rare, inherited genetic condition where patients are unable to get rid of waste nitrogen from their bodies. This then accumulates in the form of ammonia and may lead to irreversible brain damage, coma and/or death if untreated.

Read Pharma Times article